SCHEMBL196201

SCHEMBL196201

COC(=O)c1cnc(C=Cc2c(-c3ccccc3)noc2C)cc1C=Cc1c(-c2ccccc2)noc1C

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.46
ALDH1A1 P00352 3/20 0.46
GAA P10253 2/20 0.46
POLB P06746 2/20 0.46
KDM4E B2RXH2 1/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HSD17B10 Q99714 1/20 0.46
GABRA5 P31644 4/20 0.45
PTGS1 P23219 1/20 0.43
MEN1 O00255 2/20 0.42
HDAC6 Q9UBN7 4/20 0.41
HDAC1 Q13547 1/20 0.41
CASP6 P55212 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL195906 0.83 GABRA5 (0.61) ALDH1A1POLBGABRA5PTGS1CASP6
SCHEMBL195905 0.83 GABRA5 (0.61) ALDH1A1POLBGABRA5PTGS1CASP6
SCHEMBL196378 0.80 ALDH1A1 (0.46) KMT2AALDH1A1GAAPOLBKDM4E
SCHEMBL196222 0.76 PRKCE (0.34) ALDH1A1GAAPOLBKDM4ESMN1; SMN2
SCHEMBL195999 0.75 POLB (0.49) KMT2AGAAPOLBGABRA5MEN1
SCHEMBL196000 0.75 POLB (0.49) KMT2AGAAPOLBGABRA5MEN1
SCHEMBL195442 0.74 GABRA5 (0.63) GABRA5
SCHEMBL195443 0.74 GABRA5 (0.63) GABRA5
SCHEMBL14796906 0.71 GABRA5 (0.54) GABRA5
SCHEMBL285938 0.70 ALDH1A1 (0.48) ALDH1A1POLBKDM4EHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389550-B2 Isoxazoles / O-pyridines with ethyl and ethenyl linker HOFFMANN-LA ROCHE INC. (US) 2013-03-05 US disclosed
EP-2401271-A1 ISOXAZOLE / O-PYRIDINE DERIVATIVES WITH ETHYL AND ETHENYL LINKER AS GABA A ALPHA5 RECEPTOR INVERSE AGONISTS F. Hoffmann-La Roche AG (CH) 2012-01-04 EP disclosed
WO-2010097368-A1 ISOXAZOLE / O-PYRIDINE DERIVATIVES WITH ETHYL AND ETHENYL LINKER F. HOFFMANN-LA ROCHE AG (CH) 2010-09-02 WO disclosed
US-20100216845-A1 ISOXAZOLES / O-PYRIDINES WITH ETHYL AND ETHENYL LINKER ROCHE PALO ALTO LLC 2010-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216845-A1 ISOXAZOLES / O-PYRIDINES WITH ETHYL AND ETHENYL LINKER GABRA5, GABRA1, GABRA4 KMT2A 3435/4885ALDH1A1 307/4885GAA 2853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.